It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
-
The Role of Scientific Advisers in the English Patents Court
-
Trying to Make Sense of the Oracle of G 2/21: T 116/18 vs. T 681/21
-
Patent case: NanoString Technologies vs. 10x Genomics and President and Fellows of Harvard College, UPC
-
Patent case: Judgment no. 141/2023 dated 5 December 2023, Spain
Random Articles:
-
Third Party Intervention – A Multiplier for the Risk of Litigation
-
A welcome statement of diverse views or a damning indictment of a hopelessly fractured system? On the EU SEPs Expert Group report and the state of SEP licensing
-
USA: Samsung Electronics Co., Ltd. v. Apple Inc., Supreme Court of the United States, No. 15-777, 6 December 2016
-
Unified Patent Court: no second preliminary injunction for 10x Genomics against NanoString
-
Patent case: Luminaire (Leuchte), Germany
-
Despite FCC ruling, Germany wants to push ahead with Unitary Patent system
-
Concerns over proposed patent exemption for physicians and pharmacies in Switzerland
-
Brexit vote: ‘Prepared path to Unitary Patent system might not exist anymore’
-
Damages may be considered proven when the facts speak for themselves
-
Biologics, Case Law, EPC, Exceptions to patentability, Industrial application, Opposition, Second Medical Use
Dosage Regimen, European Patent Office (EPO Enlarged Board of Appeal), 19 February 2010